🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are escalating worldwide, with estimates suggesting more than 82 million instances each year. Particularly high rates are reported in Africa and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an important and timely step in the face of growing infection rates, the spread of superbugs and the highly restricted available drugs currently available.”

Medical experts are increasingly worried about the increase in drug-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance revealed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Receive Authorization

One new antibiotic, alternatively called a brand name, was authorized by the US FDA in December for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers hope that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This drug, which is additionally indicated for UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment emerged from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This milestone represents a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Outcomes and Global Access

According to data detailed in a prominent scientific publication, the new drug cured the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which uses a dual-drug approach. The trial enrolled hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the rights to make available and distribute the drug in numerous regions with limited resources.

Doctors treating patients have shared hope. Access to a one-pill regimen of this kind is hailed as a "revolutionary step" for public health efforts. This is viewed as crucial to lessen the impact of the disease for individuals and to stop the proliferation of untreatable gonorrhoea globally.